DKC1 upregulation is associated with poor prognosis in patients with prostate cancer, neuroblastoma, and hepatocellular carcinoma.27–29 These findings are consistent with our studies showing that upregulated DKC1 expression is correlated with poor 5-year overall and disease-specific cumulative survival in patients with CRC (Fig. 1e, f). The gene discussed is DKC1; the disease is hepatocellular carcinoma.